[Form 4] Hagerty, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Hagerty, Inc. (HGTY) insider reported planned sales of Class A common stock under a Rule 10b5-1 plan. Robert I. Kauffman, a director and manager of Aldel LLC, reported three dispositions on 08/26/2025–08/28/2025 totaling 67,302 shares sold at weighted-average prices of $10.76, $11.08 and $11.21 across the trades. After these transactions, Aldel LLC’s indirect beneficial ownership decreased from 1,472,463 shares to 1,415,023. The filer states the sales were executed pursuant to a 10b5-1 trading plan adopted 08/09/2024 and disclaims beneficial ownership except for pecuniary interest.
Positive
- Sales executed under a Rule 10b5-1 plan, indicating pre-planned transactions and compliance procedures
- Detailed weighted-average pricing ranges disclosed and offer to provide trade-level details on request
Negative
- Director disposed of 67,302 Class A shares, reducing indirect holdings from 1,472,463 to 1,415,023 shares
- Beneficial ownership is indirect via Aldel LLC, with the reporting person disclaiming beneficial ownership except for pecuniary interest
Insights
TL;DR: Director sold a modest portion of indirect holdings under a pre-established 10b5-1 plan; disclosure aligns with compliance norms.
The filing shows routine, pre-planned disposals rather than opportunistic trading. Use of a Rule 10b5-1 plan adopted on 08/09/2024 provides an affirmative defense to insider trading claims, and the reporting includes weighted-average prices and a commitment to provide trade-level details upon request. The director reports indirect ownership via Aldel LLC and disclaims beneficial ownership beyond pecuniary interest, which is a common governance structure for senior insiders.
TL;DR: The sales are material to insider holdings but not large enough to signal a change in control or major shift in alignment.
Total shares sold (67,302) reduced indirect holdings by about 57,440 shares net versus earliest reported balance, leaving Aldel LLC with 1,415,023 shares. The disclosed price ranges ($10.62–$11.40) are provided as weighted averages; the filing commits to share detailed execution data on request, supporting transparency for investors and regulators.